Body Dysmorphic Disorder: Symptoms, Comorbidity, Neurobiology, and Treatment Strategies

This podcast episode, hosted by Dr. Donnelly Snipes, provides a comprehensive overview of Body Dysmorphic Disorder (BDD), defining it as a preoccupation with a perceived physical flaw that is not evident to others. Sufferers spend an average of three to eight hours daily on these intrusive thoughts, leading to significant anxiety, distress, and compulsive behaviors like camouflaging. The disorder is associated with low self-esteem, shame, depressive symptoms, anxiety, and guilt, often leading to social isolation and functional impairment in academic, occupational, and relational spheres. The average age of onset is 17, with a concerningly low 20% remission rate over four years with treatment, highlighting BDD as a grossly understudied condition despite its prevalence (2% general population, 5% college/clinical population).

The episode delves into key distinctions and comorbidities, noting that BDD is now classified under the obsessive-compulsive disorder (OCD) spectrum, though insight is typically lower in BDD patients. It differentiates BDD from eating disorders and major depression, emphasizing the primary preoccupation with appearance and repetitive compulsions unique to BDD. High rates of comorbidity are discussed, including major depressive disorder (75% lifetime prevalence), anxiety disorders, OCD, substance use disorders (49%), PTSD, ADHD, social anxiety, and even compulsive sexual behavior, often used as self-medication or a means to seek acceptance. A significant finding is the high incidence of past trauma (emotional, physical, sexual abuse) among BDD sufferers, who also tend to recall these traumatic experiences more vividly.

Practical insights include the benefits of e-therapy for reducing treatment barriers, and the critical need for early intervention. Pharmacological treatments often involve SSRIs (e.g., fluoxetine, effective in 53% of cases), though higher dosages are frequently required, and no medication is FDA-approved specifically for BDD. Adjunctive treatments like bupropion (NDRI), modafinil (dopamine agonist), and buspirone are explored, as are advanced techniques like repetitive transcranial magnetic stimulation (rTMS) and deep brain stimulation (DBS) for treatment-resistant cases. Cognitive Behavioral Therapy (CBT), typically 12-22 sessions, is a cornerstone, employing strategies like exposure with response prevention (ERP), psychoeducation, motivational enhancement, cognitive restructuring, mirror training, and attention training. ERP must be gradual and professionally supervised to prevent exacerbation.

Broader implications underscore the neurobiological underpinnings of BDD, with neuroimaging studies revealing abnormal brain structure and function in occipito-temporal and fronto-limbic regions, cortical gray matter thinning, and impaired visual information processing where holistic visual input is processed as detailed-focused information. Reduced striatal dopamine D2/D3 receptor availability also points to dopaminergic pathway involvement. The misinterpretation of neutral facial expressions as contemptuous or angry further exacerbates social difficulties. The podcast advocates for a holistic treatment approach, addressing underlying trauma, exploring current triggers, leveraging strengths, and optimizing physical health through nutrition, hydration, alcohol minimization, sleep, and circadian rhythm regulation, all aimed at empowering individuals and fostering a sense of safety and well-being.